Tumor lysis syndrome in a patient with advanced lung squamous cell carcinoma undergoing combined therapy with a programmed cell death protein 1 inhibitor and first‑line chemotherapy: A case report

Cao,Li; Zhang,Wei

doi:10.3892/ol.2024.14513

Tumor lysis syndrome in a patient with advanced lung squamous cell carcinoma undergoing combined therapy with a programmed cell death protein 1 inhibitor and first‑line chemotherapy: A case report

Authors:
- Li Cao
- Wei Zhang
View Affiliations

Affiliations: Department of Oncology, The Second People's Hospital of Guiyang, Guiyang, Guizhou 550081, P.R. China, Department of Oncology, Guizhou Hospital of the First Affiliated Hospital of Sun Yat‑sen University, Guiyang, Guizhou 550003, P.R. China
Published online on: June 17, 2024 https://doi.org/10.3892/ol.2024.14513
Article Number: 380
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor lysis syndrome (TLS) is a rare but serious complication in patients with solid tumors. It is characterized by a complex array of metabolic disturbances and clinical symptoms, resulting from the release of cellular contents into the bloodstream after tumor cell lysis. The present study reports the case of a patient with advanced lung squamous cell carcinoma (SCC) who developed TLS following combined treatment with PD‑1 inhibitors and first‑line chemotherapy. The treatment strategy included intravenous fluid replacement, urine alkalinization, uric acid reduction, renal protection and electrolyte stabilization, leading to the normalization of laboratory values. After one cycle of the combined therapy, the patient achieved a partial response, classified using the Response Evaluation Criteria in Solid Tumours 1.1 criteria. To the best of our knowledge, this is the first reported case of TLS in a patient with advanced lung SCC receiving concurrent PD‑1 inhibitor and chemotherapy treatment. Given the increasing use of PD‑1 inhibitors, it is essential to remain vigilant about the potential for TLS in solid tumors. Prompt intervention in high‑risk patients, ongoing monitoring after treatment, and early detection of TLS are vital to improve patient adherence, ensure continuity of care and enhance outcomes.

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar : PubMed/NCBI
2	Morgensztern D, Waqar S, Subramanian J, Gao F and Govindan R: Improving survival for stage IV non-small cell lung cancer: A surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol. 4:1524–1529. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, et al: Updated Analysis From KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
4	Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, et al: Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 41:1999–2006. 2023. View Article : Google Scholar : PubMed/NCBI
5	Howard SC, Jones DP and Pui CH: The tumor lysis syndrome. N Engl J Med. 364:1844–1854. 2011. View Article : Google Scholar : PubMed/NCBI
6	Klemencic S and Perkins J: Diagnosis and management of oncologic emergencies. West J Emerg Med. 20:316–322. 2019. View Article : Google Scholar : PubMed/NCBI
7	Papapanou M, Athanasopoulos AE, Georgiadi E, Maragkos SA, Liontos M, Ziogas DC, Damaskos D and Schizas D: Spontaneous tumor lysis syndrome in patients with solid tumors: A scoping review of the literature. Med Oncol. 40:2332023. View Article : Google Scholar : PubMed/NCBI
8	Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V and Rami-Porta R; Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions, : IASLC lung cancer staging project: The New Database to Inform Revisions in the Ninth Edition of the TNM classification of lung cancer. J Thorac Oncol. 18:564–575. 2023. View Article : Google Scholar : PubMed/NCBI
9	Perissinotti AJ, Bishop MR, Bubalo J, Geyer MB, Goodrich A, Howard SC, Kula J, Mandayam S, Cairo MS and Pui CH: Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel. Cancer Treat Rev. 120:1026032023. View Article : Google Scholar : PubMed/NCBI
10	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, et al: NCCN Guidelines^® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023. View Article : Google Scholar : PubMed/NCBI
11	Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zhong H, Sun S, Chen J, Wang Z, Zhao Y, Zhang G, Chen G, Zhou M, Zhou J, Du Y, et al: First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): A multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 12:355–365. 2024. View Article : Google Scholar : PubMed/NCBI
13	Lee SH, Lee HT, Lim H, Kim Y, Park UB and Heo YS: Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. Biochem Biophys Res Commun. 527:226–2312. 2020. View Article : Google Scholar : PubMed/NCBI
14	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Updated Analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer With PD-L1 tumor proportion score of 50% or Greater. J Clin Oncol. 37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
15	Man J, Millican J, Mulvey A, Gebski V and Hui R: Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. JNCI Cancer Spectr. 5:pkab0122021. View Article : Google Scholar : PubMed/NCBI
16	Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G and De Marinis F: Predictive biomarkers of immunotherapy for non-small cell lung cancer: Results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res. 6:373–386. 2017. View Article : Google Scholar : PubMed/NCBI
17	Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, Ramírez A, Sesma A, Torres-Ramón I, et al: Intratumoral versus circulating lymphoid cells as predictive biomarkers in lung cancer patients treated with immune checkpoint inhibitors: Is the Easiest Path the Best One? Cells. 9:15252020. View Article : Google Scholar : PubMed/NCBI
18	Kim KH, Kim CG and Shin EC: Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Netw. 20:e82020. View Article : Google Scholar : PubMed/NCBI
19	Geng R, Tang H, You T, Xu X, Li S, Li Z, Liu Y, Qiu W, Zhou N, Li N, et al: Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. Front Immunol. 14:11258762023. View Article : Google Scholar : PubMed/NCBI
20	Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, et al: Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: Results from a single-arm phase 2 trial. Genome Med. 14:12022. View Article : Google Scholar : PubMed/NCBI